Endocrinology Medical News about Diabetic Neuropathies Pain Amitriptyline Pregabalin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09

Bansal D et al. – As there are few differences between the two treatments in efficacy, pregabalin 150 mg twice daily might be the alternative choice as it is associated with fewer adverse effects in this population.

Methods

A randomized, double–blind, crossover, active–control, clinical trial with variable dose titration was carried out (n = 51).
Amitriptyline orally, at doses of 10, 25 and 50 mg at night–time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily, by optional titration was used.
Each drug treatment was of 5 weeks.
There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.

Results

Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety.
Patient and physician's global assessment, McGill pain questionnaire, Likert pain scale and Patient Global Impression of Change showed no significant difference between the treatments, although improvement with both treatments was seen from the first week.
Of the 52 adverse events reported, 34 (65.4%) were with amitriptyline, drowsiness being the commonest [in 19 (43%) patients]. Pregabalin caused adverse events in 18 (25%), of which drowsiness was the most common in nine (20%) patients.
The preferred pregabalin dose was 150 mg twice daily.

<< Previous
Computer-aided system for health economic evaluation

Next >>
Short-term modified alternate-day fasting: a novel dietary...

Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State
Journal of Opioid Management, 11/03/09 Relevance Score: 82%

Prevalence and impact of pain in diabetic neuropathy
European Diabetes Nursing, 10/21/09 Relevance Score: 82%

New diagnostic tests for diabetic distal symmetric polyneuropathy
Journal of Diabetes and its Complications, 11/13/09 Relevance Score: 81%

A Randomized Clinical Trial of the Effectiveness of Photon Stimulation on Pain, Sensation, and Quality of Life in Patients With Diabetic Peripheral Neuropathy
Journal of Pain and Symptom Management, 11/09/09 Relevance Score: 81%

Duloxetine for treating painful neuropathy or chronic pain
Cochrane Reviews, 10/08/09 Relevance Score: 81%